The use of non-specific non-steroidal anti-inflammatory drugs (NSAIDs) is often limited by their gastrointestinal toxicity, especially in patients with known factors for increased risk of gastrointestinal adverse events [1] . The goal of developing cyclooxygenase (COX)-2-specific inhibitors such as celecoxib and rofecoxib was to circumvent the gastrointestinal toxicity of non-specific NSAIDs by sparing the gastroprotective COX-1 isoenzyme while maintaining efficacy through specific targeting of the proinflammatory COX-2 isoenzyme. The efficacy of these drugs in providing symptomatic relief of painful and inflammatory conditions and their improved gastrointestinal safety/tolerability relative to non-specific NSAIDs has been demonstrated in individual and pooled analyses of clinical trials, outcomes studies, and a recent meta-analysis [2] [3] [4] [5] [6] [7] [8] .
Since their introduction, COX-2-specific inhibitors have become a rapidly growing segment of the prescription drug market, especially in patients with osteoarthritis (OA) and rheumatoid arthritis (RA). However, the higher drug acquisition costs of COX-2-specific inhibitors relative to non-specific NSAIDs has resulted in restrictions on their use in the UK [9] and recommendations for restricted use in some provinces within Canada [10] .
Canadian provincial drug plan reimbursement policies for COX-2-specific inhibitors vary by province, ranging from full reimbursement in Que´bec (Liste de medicaments, La Re´gie de l'assurance maladie du Que´bec) to limited restrictions in Ontario (Ontario Drug Benefit Formulary/Comparative Drug Index, Ontario Drug Benefit Program) and severe restrictions in British Columbia (British Columbia PharmaCare Program). In Ontario, the restrictions are in the form of limited use (LU) criteria, which theoretically need to be met by patients in order for the prescription to be eligible for reimbursement. According to these criteria, reimbursement of COX-2-specific inhibitors for treatment of OA will be allowed 'for patients who have failed an adequate trial of acetaminophen (e.g. acetaminophen 1 g QID for several weeks) and have had: 1. History of a serious ulcer-related complication (i.e. perforation, gastrointestinal bleed, or clinically significant ulcer); or 2. Failure or intolerance to at least three listed NSAIDs' [11] . Since acetaminophen (paracetamol) is not effective for RA, only the second set of criteria applies for prescribing a COX-2-specific inhibitor for this condition [11] . However, the proportion of patients using COX-2-specific inhibitors who are eligible for reimbursement under these LU criteria has not been investigated.
The purpose of the present study was to determine what proportion of patients eligible for reimbursement of celecoxib met the LU criteria. Such information not only indicates the extent of adherence to suggested guidelines, but can also be used as a measure of appropriate prescribing patterns under the LU criteria.
Methods
Two approaches were used to determine compliance with the LU criteria. The first method was a prospective patient-based survey carried out through community-based pharmacies in which pharmacy recruitment of prospective subjects was the method of data collection. This prospective patient-based survey underwent ethics review which was performed by Institutional Review Board Services. Pharmacies were first screened by postal code in order to obtain a group of pharmacies representative of the demographics of Ontario. Forty pharmacies were selected for participation in the study, and selected pharmacists responsible for the conduct of the study were trained in good clinical practice, in the administration of the study questionnaire and in the procedures for transmittal and storage of patient case report forms. Pharmacists maintained screening and enrolment logs, and screened subjects who presented with a script for celecoxib eligible for reimbursement according to pre-established eligibility criteria (age >18 years, ability to communicate adequately in English and willingness to provide written informed consent to participate in the study). Subjects who satisfied these predetermined criteria were approached for consent, and a questionnaire on medical and drug history was administered with the pharmacist's assistance and availability to clarify any questions the subjects may have.
The second approach was a retrospective analysis using the Ontario Drug Benefit (ODB) Program database of prescription level claims data maintained by Brogan Inc. The ODB Program records prescription drugs dispensed to all Ontario residents aged 65 yr or older. The ODB database only compiles data on dispensed prescription drugs that are eligible for reimbursement. Celecoxib was listed for reimbursement on the ODB formulary as of 17 April 2000. The database does not include hospitalization records. All beneficiaries (identified with a consistently applied scrambled identification) from the ODB Program database were selected based on an ODB-reimbursed prescription for celecoxib dispensed between May 2000 and March 2002 (index period). Starting from April 1992, previous drug claims for non-specific NSAIDs, paracetamol and gastroprotective agents were reviewed from the ODB Program database in order to define the prescription history of the population of interest. This information was used to conduct the drug utilization analysis.
Sessions with physician focus groups and external scientific advisers were conducted in order to formulate operational definitions for the LU criteria.
The variation in practice patterns in combination with the differing patient characteristics in different medical practices (e.g. family practitioner vs rheumatology and community care vs academic setting) and the heterogeneity of the data sources necessitated that a spectrum of operational definitions be agreed upon for the purposes of the analyses. The spectrum of definitions presented in the analyses ranged from a literal interpretation of the LU criteria as the baseline analysis, to the broader, more pragmatic definitions as presented by the clinicians and interpreted by the subjects participating in the study. It is this spectrum of operational definitions that has been used in reporting the study results, in recognition of variations between the accepted definitions according to medical specialties and the characteristics of the patient population specific to any given medical practice. Table 1 presents the focus-group interpretations of clinically relevant rigorous definitions and more pragmatic definitions applied to both methodological approaches. Given the lack of documentation within the ODB Program database as to the occurrence and severity of gastrointestinal complications, its review could be conducted exclusively in the light of the pragmatic definitions.
Results
Study populations included 876 patients in the patientbased survey and 147 208 patients in the database analysis. Table 2 presents the patient characteristics of both populations and shows that the majority of the patients were elderly (mean age in the patient-based survey was 72.1 ± 10.0 yr), more than half were female, and 84% had a pharmacy-reported diagnosis of OA. Subjects in the patient-based survey had a long self-reported duration of arthritis (12.9 ± 11.8 yr), encompassing OA, RA and unspecified arthritis. Table 3 shows the rates of adherence to the LU criteria for patients with OA and RA in both the patient-based survey and the database analysis. Among patients with OA or RA, use of the pragmatic definition resulted in a higher proportion of patients meeting the LU criteria for reimbursement of celecoxib regardless of whether the criteria were based on history of gastrointestinal problems or prior use of 3 NSAIDs. However, a higher proportion of patients met the LU criteria based on history of gastrointestinal problems than on prior NSAID use regardless of which definition was used. Almost all patients, 97% in the patient-based survey and 94% in the database, had one or more factors for increased risk for gastrointestinal complications.
For OA, a higher proportion of patients met LU criteria according to the database (76%) than in the patient-based survey (53%), while for RA the proportion of patients meeting LU criteria was similar in the patientbased (81%) and database surveys (78%).
As a secondary consideration, the proportion of patients taking celecoxib who were coprescribed gastroprotective agents (proton pump inhibitors, histamine-2 receptor antagonists, and prostaglandin analogues) was determined and is shown in Table 4 . This proportion was similar in both the patient-based survey (38%) and the database analysis (41%). A high proportion of patients in both populations (approximately 90%) had prior use of gastroprotective agents, but according to information obtained from the database, the proportion of patients previously taking these agents in the absence of concomitant NSAID use was low (4%).
Discussion
Recall bias is a potential limitation in studies such as a pharmacy-based study that requires patients to recall and report their medical and drug history. For many reasons, including lack of information and poor communication between health-care providers and subjects, patients do not always report medical and treatment history accurately. It is especially difficult for a subject to accurately recall past medical history beyond the short term or to recall past medication use in general [12] . Additionally, patient-reported information may be less reliable in older populations; in the present study the majority of patients were over the age of 65 yr. For this reason, a retrospective database analysis was also used. The observed discrepancies in results between the methodological approaches partially testify to the issue of adequate subject recall of medical history. These discrepancies may also be partially attributable to a non- An adequate trial of acetaminophen was defined as any dose used for the treatment of OA at any time in the past (current use not excluded). An adequate trial of NSAIDs was defined as a 1-to 4-week trial of any NSAID used for the treatment of OA at any time in the past.
An adequate trial of NSAIDs was defined as any dose of any NSAID for the treatment of arthritic symptoms at any time in the past (regardless of failure or side-effects). A serious ulcer-related GI complication was defined as the current or prior presence of any gastric ulcer, GI bleeding, perforation, obstruction or melena.
A serious ulcer-related GI complication was defined as the current or prior presence of gastric ulcer, GI bleeding, perforation, obstruction or melena, or the presence of any potentially serious GI disorder including gastroesophageal reflux disease and unrelieved dyspepsia (for the prospective patient-based survey). The dispensation of medications used for the relief of GI symptoms is used as a proxy assessment for GI complications within the retrospective analysis of the ODB database. RA An adequate trial of NSAIDs was defined as a 1-to 4-week trial of any NSAID used for the treatment of RA at any time in the past.
An adequate trial of NSAIDs was defined as any NSAID used for the treatment of RA at any time in the past (regardless of failure or side-effects). A serious ulcer related GI complication was defined as the current or prior presence of any gastric ulcer, GI bleeding, perforation, obstruction or melena.
A serious ulcer-related GI complication was defined as the current or prior presence of gastric ulcer, GI bleeding, perforation, obstruction or melena, or the presence of any potentially serious GI disorder including GERD and unrelieved dyspepsia (for the prospective patient-based survey). The dispensation of medications used for the relief of GI symptoms is used as a proxy assessment for GI complications within the retrospective analysis of the ODB database. representative sample of subjects and to the differences inherent to the data used.
Nevertheless, the data reported in this drug utilization review suggest that, at least for celecoxib, not only is there physician compliance with reimbursement guidelines based on LU criteria, but there is also appropriate prescribing of celecoxib by physicians to patients who appear to be at increased risk of gastrointestinal events.
Although a full risk factor analysis was not part of this study, the increased age of the population and the presence of prior gastrointestinal adverse events are both significant factors for increased risk of serious gastrointestinal events among patients taking non-specific NSAIDs [1] . This prescribing of celecoxib to patients at increased risk of gastrointestinal events is suggestive of channelling and may indicate that physicians are prescribing celecoxib in accordance with recommended guidelines. Such channelling has previously been described for COX-2-specific inhibitors [13, 14] and is discussed elsewhere in this supplement [15] .
Patients taking non-specific NSAIDs switch frequently from one non-specific NSAID to another because of gastrointestinal intolerability or loss of efficacy [16, 17] . The long duration of arthritis among the patient-based population in this study suggests that these patients are likely to have tried multiple non-specific NSAIDs, and thus disease duration by itself may be enough to meet reimbursement criteria.
Although paracetamol has been recommended by the American College of Rheumatology (ACR) as first-line treatment for OA [18] , not only because of its lower cost but also because of its supposedly lower gastrointestinal toxicity relative to non-specific NSAIDs, recent evidence suggests that its gastrointestinal toxicity has been underestimated [19] . Additionally, patient preference for paracetamol for the treatment of OA is low compared with other available agents, primarily due to patient reports of poor analgesic efficacy [20, 21] , which has been confirmed in a recent trial [22] . However, in contrast to the ACR recommendations, current Canadian consensus suggests that, while paracetamol remains an option, most patients presenting to a physician will have already tried it unsuccessfully, and therefore other alternatives should be considered as first-line therapy [23] . Under these consensus guidelines, reimbursement criteria using the pragmatic definition seem appropriate and are likely to be met by many of the patients requiring use of celecoxib.
While the majority of patients in this study met the LU criteria for reimbursement, the problem with restricted drug use is that some patients who should be taking COX-2-specific inhibitors are not. For example, there are other important factors that should be considered in physician prescribing of these drugs but that are not included in the LU criteria. These factors include the use of oral anticoagulants or corticosteroids. The importance of these factors to clinical and economic outcomes may equal or exceed those provided by the allowances of the LU criteria.
The effect on implementing reimbursement restrictions on prescribing and the utilization of these drugs is graphically shown in Fig. 1 , which presents the market share of COX-2-specific inhibitors as reimbursed by the public drug programs in Que´bec and Ontario. These drugs are more widely used in Que´bec, where they are fully reimbursed. Since the purpose of imposing restrictions is to contain costs, it is important to determine whether reimbursement restrictions, such as those represented by LU criteria, result in long-term clinical and economic benefits or merely offer short-term cost containment by reducing drug acquisition costs.
A high proportion of patients who were prescribed celecoxib in this study were concomitantly prescribed gastroprotective agents. However, the reason for the use of these agents was not determined, and it is likely that for some of these patients the use of these agents is for symptoms, such as dyspepsia and gastro-oesophageal There are several limitations associated with this study. For the patient-based analysis, as mentioned previously, patient-recall bias represents a probability that could not be controlled for. Similarly, there may be an inherent selection bias in those who chose to participate in the study. These biases may be compounded by the lack of data in pharmacy records that can be used for validation purposes, thereby relying predominantly on possibly biased patient reporting.
The database analysis is limited by the use of drug claims as a proxy for medical variables, with little additional information provided on the use of over-thecounter drugs or drugs not reimbursed by the ODB. Nevertheless, the database analysis is very reliable as far as reimbursed drug utilization is concerned. Reimbursement of a drug claim for a patient is a sufficient economic incentive to ensure that his drug utilization will be captured, when eligible, as part of the public drug programme administrative database. As such, when exclusively looking at the portion of the criteria that pertains to drug use, i.e. the previous use of paracetamol and of three or more listed NSAIDs, 50% of claimants complied with the LU criteria (Table 3) , as observed from the database analysis. This 50% represents the lower bound of adherence to the LU criteria in OA patients. The adherence is therefore very likely greater than 50% when adding to the adherence count of subjects who experienced serious gastrointestinal problems.
While this study suggests that the majority of celecoxib prescriptions in Ontario are consistent with the LU criteria, it also highlights the need for improving prescriber and patient awareness of risks associated with OA and RA treatment strategies. Further investigations are needed to determine how LU criteria impact long-term clinical and economic outcomes.
